NCT02387606View on ClinicalTrials.gov

Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection.

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

May 7, 2015

Primary Completion Date

September 21, 2015

Study Completion Date

October 2, 2015

Conditions
Respiratory Syncytial Virus Infections
Interventions
DRUG

Placebo

Participants will receive placebo once daily.

DRUG

JNJ-53718678

Participants will receive JNJ-53718678 as 20 milliliter (mL) (200 mg) or 50 mL (500 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 1. JNJ-53718678 dose in Cohort 2 will be decided based on Cohort 1 results. JNJ-53718678 as 7.5 mL (75 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 3.

Trial Locations (1)

Unknown

London

All Listed Sponsors
lead

Janssen Sciences Ireland UC

INDUSTRY

NCT02387606 - Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection. | Biotech Hunter | Biotech Hunter